Blueprint Medicines. has filed a patent for compounds of Formula (I) for treating diseases related to mutant KIT and PDGFRa. The compounds offer a non-brain penetrant profile and are useful for treating gastrointestinal stromal tumors and systemic mastocytosis. GlobalData’s report on Blueprint Medicines gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Blueprint Medicines Corp - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Blueprint Medicines, Cancer treatment biomarkers was a key innovation area identified from patents. Blueprint Medicines's grant share as of January 2024 was 30%. Grant share is based on the ratio of number of grants to total number of patents.

The patent application (Publication Number: US20240010652A1) discloses a compound of Formula (I) and its various derivatives, including those represented by Formulas (II) and (III). The compounds encompass pharmaceutically acceptable salts and/or solvates, with specific variations in the chemical structure denoted by X1 and X2. Additionally, the patent covers pharmaceutical compositions containing these compounds along with suitable excipients for medical use.

Furthermore, the patent application outlines a method for treating various diseases or conditions in patients by administering the disclosed compounds. The diseases targeted include systemic mastocytosis, gastrointestinal stromal tumors, acute myeloid leukemia, melanoma, and several others. Specifically, the method focuses on utilizing the compounds for treating systemic mastocytosis, with further distinctions made between indolent systemic mastocytosis and smoldering systemic mastocytosis. Overall, the patent application provides a comprehensive framework for the development and application of these compounds in the field of pharmaceuticals for treating a range of medical conditions.

To know more about GlobalData’s detailed insights on Blueprint Medicines, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies